TY - JOUR
T1 - Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody
AU - Stangl, Stefan
AU - Gehrmann, Mathias
AU - Riegger, Julia
AU - Kuhs, Kristin
AU - Riederer, Isabelle
AU - Sievert, Wolfgang
AU - Hube, Kathrin
AU - Mocikat, Ralph
AU - Dressel, Ralf
AU - Kremmer, Elisabeth
AU - Pockley, Alan G.
AU - Friedrich, Lars
AU - Vigh, Laszlo
AU - Skerra, Arne
AU - Multhoff, Gabriele
PY - 2011/1/11
Y1 - 2011/1/11
N2 - Immunization of mice with a 14-mer peptide TKDNNLLGRFELSG, termed "TKD," comprising amino acids 450-461 (aa450-461) in the C terminus of inducible Hsp70, resulted in the generation of an IgG1 mousemAb cmHsp70.1. The epitope recognized by cmHsp70.1 mAb, whichhas beenconfirmed tobelocated in theTKD sequence by SPOT analysis, is frequently detectable on the cell surface of human and mouse tumors, but not on isogenic cells and normal tissues, and membrane Hsp70 might thus serve as a tumor-specific target structure. As shown for human tumors, Hsp70 is associated with cholesterol-rich microdomains in the plasma membrane of mouse tumors. Herein, we show that the cmHsp70.1 mAb can selectively induce antibody-dependent cellular cytotoxicity (ADCC) of membrane Hsp70+ mouse tumor cells by unstimulated mouse spleen cells. Tumor killing could be further enhanced by activating the effector cells with TKD and IL-2. Three consecutive injections of the cmHsp70.1 mAb into mice bearing CT26 tumors significantly inhibited tumor growth and enhanced the overall survival. These effects were associated with infiltrations of NK cells, macrophages, and granulocytes. The Hsp70 specificity of the ADCC response was confirmed by preventingthe antitumor response in tumor-bearingmiceby coinjecting the cognate TKD peptide with the cmHsp70.1 mAb, and by blocking the binding of cmHsp70.1 mAb to CT26 tumor cells using either TKD peptide or the C-terminal substrate-binding domain of Hsp70.
AB - Immunization of mice with a 14-mer peptide TKDNNLLGRFELSG, termed "TKD," comprising amino acids 450-461 (aa450-461) in the C terminus of inducible Hsp70, resulted in the generation of an IgG1 mousemAb cmHsp70.1. The epitope recognized by cmHsp70.1 mAb, whichhas beenconfirmed tobelocated in theTKD sequence by SPOT analysis, is frequently detectable on the cell surface of human and mouse tumors, but not on isogenic cells and normal tissues, and membrane Hsp70 might thus serve as a tumor-specific target structure. As shown for human tumors, Hsp70 is associated with cholesterol-rich microdomains in the plasma membrane of mouse tumors. Herein, we show that the cmHsp70.1 mAb can selectively induce antibody-dependent cellular cytotoxicity (ADCC) of membrane Hsp70+ mouse tumor cells by unstimulated mouse spleen cells. Tumor killing could be further enhanced by activating the effector cells with TKD and IL-2. Three consecutive injections of the cmHsp70.1 mAb into mice bearing CT26 tumors significantly inhibited tumor growth and enhanced the overall survival. These effects were associated with infiltrations of NK cells, macrophages, and granulocytes. The Hsp70 specificity of the ADCC response was confirmed by preventingthe antitumor response in tumor-bearingmiceby coinjecting the cognate TKD peptide with the cmHsp70.1 mAb, and by blocking the binding of cmHsp70.1 mAb to CT26 tumor cells using either TKD peptide or the C-terminal substrate-binding domain of Hsp70.
KW - Cellular cytotoxicity
KW - Epitope mapping
KW - Immunotherapy
KW - Surface antigen
KW - Syngeneic tumor model
KW - Tumor antibody dependent
UR - http://www.scopus.com/inward/record.url?scp=79551657031&partnerID=8YFLogxK
U2 - 10.1073/pnas.1016065108
DO - 10.1073/pnas.1016065108
M3 - Article
C2 - 21187371
AN - SCOPUS:79551657031
SN - 0027-8424
VL - 108
SP - 733
EP - 738
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 2
ER -